WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.

Trial Profile

WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.

Suspended
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Leukaemia DNA vaccine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms WIN
  • Most Recent Events

    • 29 Jun 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
    • 10 Jan 2013 Accrual to date is 12% according to United Kingdom Clinical Research Network.
    • 06 Dec 2012 Based on positive interim findings in 8 vaccinated patients with HLA-A2 positive chronic myeloid leukaemia, enrolment has been opened to patients with acute myeloid leukaemia according to an Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top